IgA Tarpeyo denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for iga tarpeyo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Denies Tarpeyo as Experimental — and Why That Denial Is Appealable

A denial labeling Tarpeyo (budesonide delayed-release capsules) as "experimental" or "investigational" is difficult to sustain given that the FDA granted Tarpeyo full approval for the treatment of primary IgA nephropathy. UnitedHealthcare's experimental-use exclusions are legally and contractually designed to cover drugs that have not yet completed the regulatory approval process — not drugs bearing a current FDA approval for the exact indication being treated.

This type of denial most often arises when a plan's drug-tier database has not been updated to reflect a recent FDA approval, or when a reviewer misapplies an older policy that pre-dates the drug's approval date. It is one of the most routinely overturned denial categories at both the internal-appeal and external-review stages.

## Your Federal Appeal Rights

• ACA §2719: Non-grandfathered plans must provide internal appeals and binding external review by an accredited IRO. External reviewers are specifically empowered to reverse experimental denials when a drug holds an FDA approval for the claimed indication.
• ERISA §503: Employer plan members are entitled to a full-and-fair review with access to the clinical criteria the plan used.
• Timeline: File your internal appeal within 180 days of the denial notice. External review requests are generally due within approximately four months of exhausting internal remedies. If your kidney function is actively deteriorating, invoke the expedited-review pathway, which compresses the decision window to 72 hours.

## Documentation to Gather Before You Appeal

1. FDA approval confirmation — download and attach the FDA drug-approval page for Tarpeyo showing the approved indication and approval date. 2. Diagnosis documentation — biopsy or pathology report confirming primary IgA nephropathy; treating nephrologist's notes confirming the diagnosis. 3. Prescriber letter — a letter from your nephrologist affirming that the prescription is for the FDA-approved indication and explaining why, in their clinical judgment, the drug is medically necessary. 4. UHC's own policy — pull UHC's current published coverage policy and confirm whether it has been updated post-approval; if the policy date predates the FDA approval, flag that explicitly in your appeal letter. 5. Applicable guideline reference — your nephrologist may reference the relevant nephrology society guideline recommendation without citing specific statistics.

## Criteria-Mapping Structure

Open your appeal letter by stating the FDA approval date and indication verbatim from the label. Follow with a side-by-side table: UHC's denial rationale in the left column, the specific rebuttal evidence in the right column. Your central argument should be a single clear sentence: this drug holds FDA approval for the precise indication being treated, so the experimental exclusion does not apply as a matter of plan terms and federal law.